Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
12:05pm, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK – Research Report) today and set
Mizuho Securities Believes Iovance Biotherapeutics (IOVA) Still Has Room to Grow
09:46am, Monday, 27'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (IOVA) today and set a price target of $61.00. The company's
Mizuho Securities Believes Iovance Biotherapeutics (NASDAQ: IOVA) Still Has Room to Grow
09:46am, Monday, 27'th Apr 2020
Mizuho Securities analyst
Mara Goldstein
reiterated a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) today and set a price target of
$61.00
. The company’s shares closed last Fri
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s
Merck & Company (MRK) Receives a Buy from Mizuho Securities
02:55pm, Thursday, 23'rd Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK), with a price target of $100.00.
Merck & Company (MRK) Receives a Buy from Mizuho Securities
02:55pm, Thursday, 23'rd Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK –
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020
12:30pm, Wednesday, 22'nd Apr 2020
BURLINGAME, Calif., April 22, 2020 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization.
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
Mizuho Securities analyst Mara Goldstein initiated coverage with a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $3.00.
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
Mizuho Securities analyst
Mara Goldstein
initiated coverage with a
Hold
rating on Adaptimmune Therapeutics (
ADAP
–
Research Report
) today and set a price target of
$3.00
. The company’s shares c
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL) and a price target
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Iovance Biotherapeutics (IOVA) and a price
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
08:16pm, Tuesday, 21'st Apr 2020
In a report released today,
Mara Goldstein
from Mizuho Securities initiated coverage with a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) and a price target of
$61.00
. The compan
Incyte (INCY) Gets a Hold Rating from Mizuho Securities
12:08am, Monday, 20'th Apr 2020
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Incyte (INCY), with a price target of $79.00. The
Incyte (INCY) Gets a Hold Rating from Mizuho Securities
12:08am, Monday, 20'th Apr 2020
In a report released yesterday,
Mara Goldstein
from Mizuho Securities maintained a
Hold
rating on Incyte (
INCY
–
Research Report
), with a price target of
$79.00
. The company’s shares closed las
